BOARD OF DIRECTORS

Craig Fraser

Craig Fraser joined Windtree in February of 2016 as President and Chief Executive Officer. He was also appointed to serve as a member of the Board of Directors in February 2016.

Mr. Fraser brings over 30 years of experience as a leader in both product development and commercial operations, and in building biopharmaceutical and device businesses for both startups and larger companies. Prior to joining Windtree, Mr. Fraser held executive positions at several biopharmaceutical companies, including as Chief Operating Officer at Novelion (AEGR) Pharmaceuticals, Vice

President of Global Disease Areas at Pfizer, Vice President and Global Business Manager at Wyeth, and Vice President of Sales & Marketing and Commercial Operations at Johnson & Johnson / Centocor. Mr. Fraser is a veteran of both the U.S. Marine Corps and the U.S. Army.

Mr. Fraser received his B.S. degree from Slippery Rock University of Pennsylvania.

Leanne Kelly

Ms. Kelly has served as GRI Bio’s Chief Financial Officer since April 2023. She brings over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce sectors with a foundation in public accounting. Prior to joining GRI Bio, she most recently served as Chief Financial Officer of Vallon Pharmaceuticals from May 2021 until April 2023. Previously, she was Controller and Executive Director, Global Financial Reporting at OptiNose, Inc. from 2016 to 2021. Over the course of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as Flower Orthopedics from 2013 to 2016, Iroko Pharmaceuticals, LLC in 2013, and Genaera Corporation from 2002 to 2009. Ms. Kelly received her undergraduate degree in business economics with a concentration in accounting from Lehigh University and is a licensed CPA (inactive status) in the state of Pennsylvania.

Jed Latkin

Jed Latkin has nearly three decades of experience with financial and biotech companies. Jed’s experience includes serving as the Chief Operating Officer and head of Finance for ProPhase Labs, Inc. since January 2023, and as the Chief Executive Officer of Navidea Biopharmaceuticals, Inc., where he raised over $160 million and arranged a key transaction for Navidea that resulted in consideration up to $310 million. While at Navidea, he also served as the Chief Financial Officer prior to becoming the Chief Executive Officer. In connection with his role at Nagel Avenue Capital, he also served as Chief Executive Officer of Black Elk Energy Offshore in 2014. Jed started his career by spending ten years on Wall Street with a variety of investment banking organizations and funds including ING, Morgan Stanley and Citigroup Securities.

Saundra Pelletier​

Saundra Pelletier has served as the Interim Chair since late 2021 and as Chief Executive Officer, President and Executive Director since early 2015 of Evofem Biosciences, Inc., a commercial-stage biopharmaceutical company focused on commercializing innovative products to address unmet needs in women’s health. Ms. Pelletier brings more than twenty-five years of broad executive leadership experience to Windtree’s board, including successes in driving multiple, billion-dollar product launches, expanding organizational capabilities in ex-U.S. markets and advocating for women’s health. Throughout her career, she has had oversight and accountability for nearly all aspects of commercialization, manufacturing and medical and business development. Saundra has also served on the board of directors for TRACON Pharmaceuticals, Inc., since early 2020, which is focused on developing novel oncology therapeutics.

Dr. Mark Strobeck